Assessing prostate cancer tissue using a fine needle probe
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
This study is testing a new fine needle probe that uses light and sound to check for prostate cancer without taking tissue samples during biopsies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | Male |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Trial ID | NCT05965180 on ClinicalTrials.gov |
What this trial studies
This project integrates Photoacoustic (PA) technology into prostate biopsy procedures using a fine needle probe designed to work with transrectal ultrasound (TRUS). The probe will assess histological information from surrounding prostate tissue without extracting any samples. It has previously been tested on prostate tissue samples and whole human prostates in ex vivo conditions. The goal is to enhance the accuracy of prostate cancer assessments during routine biopsies.
Who should consider this trial
Good fit: Ideal candidates are men aged 40 to 80 who are scheduled for a prostate biopsy as part of their routine clinical care.
Not a fit: Patients with bleeding disorders, those on anticoagulants, or individuals who cannot provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of prostate cancer without the need for tissue extraction.
How similar studies have performed: While this approach is innovative, similar studies using photoacoustic technology in other contexts have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Planned prostate biopsy as part of routine clinical care * 2\) \> 40 and \<80 years old Exclusion Criteria: * 1\) Known history of bleeding disorders or * 2\) Patients taking anticoagulants, no matter doses or washout time * 3\) Known allergy to silicone material * 4\) Unable to provide informed consent * 5\) Either the surgeon or the patient do not think the patient will not be able to complete all parts of the study, the patient will be excluded * 6\) Involved in other investigational studies.
Where this trial is running
Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Guan Xu, Phd — University of Michigan
- Study coordinator: Cancer AnswerLine
- Email: CancerAnswerLine@med.umich.edu
- Phone: 1-800-865-1125
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.